Biostem Technologies

Biostem Technologies Equity Ratio

The Equity Ratio of Biostem Technologies (BSEM) as of Nov 19, 2026 is 29.12 %. In the previous year, Equity Ratio was -6.76 % — a change of -531.01% (higher).

Equity Ratio

29.12 %

YoY

-531.01%

Last updated:

Equity Ratio of Biostem Technologies is 2024 29.12 % . Equity Ratio of Biostem Technologies was 2023 -6.76 % . It decreases by -531.01% higher compared to the previous year.

The Biostem Technologies Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2017
48.25 USD
Jan 1, 2018
-38.89 USD
Jan 1, 2019
-124.81 USD
Jan 1, 2020
-211.10 USD
Jan 1, 2021
-216.88 USD
Jan 1, 2022
-113.95 USD
Jan 1, 2023
-6.76 USD
Jan 1, 2024
29.12 USD
The Biostem Technologies Equity Ratio history
YEAREquity RatioYoY
29.12 %-531.01%
-6.76 %-94.07%
-113.95 %-47.46%
-216.88 %+2.74%
-211.10 %+69.15%
-124.81 %+220.93%
-38.89 %-180.60%
48.25 %+174.60%
17.57 %-68.63%
56.00 %-34.06%
84.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostem Technologies stock

Equity Ratio of Biostem Technologies is 29.12 % in 2024.

Equity Ratio of Biostem Technologies changed from -6.76 % to 29.12 %, representing a -531.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Biostem Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Biostem Technologies

All Key Metrics — Biostem Technologies